Form 4: Werewolf Therapeutics CEO Granted Stock Options
SEC Form 4 Filing
Werewolf Therapeutics CEO, Daniel J. Hicklin, was granted stock options on January 2, 2025, according to a recent SEC filing.
Summary
- Daniel J. Hicklin, CEO of Werewolf Therapeutics, was granted stock options on January 2, 2025.
- The options are for 592,690 shares with an exercise price of $1.56 and expire on December 31, 2034.
- An additional 185,652 options were granted with the same exercise price and expiration date, but with an exercisable date of January 2, 2027.
- The options vest in equal monthly installments over four years, starting one month after the vesting commencement date of January 1, 2025, and continuing through January 1, 2029.
Sentiment
Score: 7
Explanation: The document is a routine SEC filing regarding stock options granted to the CEO, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Management Comments
- The filing was signed by Jonathan Owen, Attorney-in-fact, on behalf of Daniel J. Hicklin.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation in the biotech industry.
- The vesting schedule of four years is typical for such grants, ensuring long-term alignment.
- The exercise price of $1.56 is not directly comparable without knowing the current market price of the stock, but is a common practice.
Stakeholder Impact
- The stock option grant may be viewed positively by shareholders as it incentivizes the CEO to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 01/01/2025 | Vesting Commencement Date for the stock options. |
| 01/02/2025 | Date the stock options were granted. |
| 01/02/2027 | Exercisable date for 185,652 of the stock options. |
| 12/31/2034 | Expiration date for all stock options. |
| 01/06/2025 | Date of the SEC filing. |
Keywords
stock options, executive compensation, SEC Form 4, Werewolf Therapeutics, Daniel J. Hicklin, equity, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.